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A B S T R A C T   
Background: Despite treatment with radical cystectomy, patients with muscle invasive bladder cancer (MIBC) 
have a poor survival. It has been reported that survival is worse in NMIBC patients who progressed to MIBC in 
comparison to patients with de novo MIBC. The objective of this study was to compare survival of progressive 
versus de novo MIBC. Secondary objective was to explain this difference in survival by clinicopathological factors. 
Methods: 431 patients with MIBC who underwent radical cystectomy between 1998 and 2016 in the Radbou-
dumc, Nijmegen, were retrospectively analyzed. 313 patients were identified with de novo MIBC and 118 with 
progressive MIBC. 
Results: 5- and 10-year overall survival (OS) of patients with progressive MIBC was 37% and 20%, respectively. 
Patients with de novo MIBC had significantly better survival, with a 5- and 10-year OS of 49% and 39%, 
respectively. Patients with progressive MIBC were more frequently diagnosed with concomitant carcinoma in 
situ and positive surgical margins in bladder, ureters or urethra. In multivariable analysis that adjusted for these 
factors, progressive MIBC was associated with a hazard ratio of 1.40 (0.99 – 1.98). Kaplan-Meier survival curves 
show a detrimental effect of progressive MIBC in patients with pT2 versus pT3–4 tumors and in patients with 
negative versus positive surgical margins. In multivariable analysis, this effect modification disappeared. 
Conclusions: Progressive MIBC is associated with poorer survival than de novo MIBC. Because most patients with 
progressive MIBC had a history of high risk NMIBC, considering radical cystectomy is most important in the 
highest risk NMIBC.   
Microabstract 
To examine if patients with muscle invasive bladder cancer have 
worse survival in case they were initially diagnosed with non-muscle 
invasive bladder cancer, a retrospective analysis has been performed. 
A clear difference in survival was detected. However, this difference 
could not be explained by the clinicopathological factors analyzed. 
Introduction 
Bladder cancer is the 12th most diagnosed cancer with approxi-
mately 550,000 new cases worldwide in 20181. For clinical practice it is 
important to distinguish non-muscle invasive bladder cancer (NMIBC) 
from muscle invasive bladder cancer (MIBC). The vast majority, about 
75% of all patients, will initially be diagnosed with NMIBC. NMIBC is 
known for its high recurrence rate and moderate risk of progression into 
MIBC, depending on stage and grade. For high risk NMIBC, the esti-
mated 5-year risk of progression is approximately 20%2. 
Currently, the ‘gold standard’ treatment for MIBC is radical cys-
tectomy (RC) with bilateral pelvic lymphadenectomy. Nonetheless, 
MIBC has a 5-year survival of only 50% after RC3. In NMIBC cystectomy 
is seldom performed, and restricted to highly selected patients with a 
high risk of recurrence and/or progression. Cystectomy is a treatment 
with a high morbidity and a strong impact on quality of life, but it 
provides good survival in patients with NMIBC. The 10-year 
disease-specific survival in patients with lymph node negative high 
risk NMIBC is up to 90%4. 
Interestingly, several previous studies reported a much worse sur-
vival in patients with NMIBC who progressed to MIBC compared to 
patients with de novo MIBC5. However, contradicting studies have been 
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published as well (see Table 1). Because of the different study results, the 
primary objective of this single center study is to examine whether pa-
tients with progressive MIBC have a worse survival compared to patients 
with de novo MIBC. Secondary objective is to determine if clinicopath-
ological factors can explain the hypothesized difference in survival. 
Materials and methods 
Patients 
A historical cohort study was performed in 782 patients who un-
derwent a cystectomy between 1998 and 2016 in the Radboudumc, 
Nijmegen, the Netherlands. 132 patients were excluded because cys-
tectomy was not performed because of bladder cancer, but because of 
functional complaints or malignancies other than bladder cancer, such 
as prostate cancer or bladder-invading sigmoid cancer. In another 180 
patients, the histology was not urothelial cell MIBC that resulted in 
exclusion of these patients. A further 37 patients were excluded because 
either cystectomy was not intended to be curative or because of Clavien- 
Dindo grade 5 complications, which means death of the patient occurred 
during hospitalization. 2 patients were excluded because of concomitant 
upper tract tumors. Cystectomies were performed in the Radboudumc. 
Being a tertiary medical center, most of the NMIBC diagnoses, treat-
ments and MIBC diagnoses took place in referring hospitals. 
Diagnosis of MIBC was established by transurethral resection of the 
bladder tumor (TURBT). Lymph node metastases or distant metastases 
were diagnosed by CT or MRI. Clinical and pathological staging was 
performed according to the TNM classification system. If lymph node 
metastases were expected, induction chemotherapy was advised if 
feasible. 
Patients were divided into two different groups: patients with MIBC 
at initial presentation (de novo MIBC) and patients with a history of 
NMIBC, that progressed to MIBC (progressive MIBC). Prior NMIBC was 
treated by TURBT and subsequent intravesical chemotherapy or 
immunotherapy (with Bacillus Calmette-Guérin (BCG)). For patients 
who were referred to our clinic, information about previous NMIBC 
diagnoses, if any, including pathology reports was obtained from the 
referring hospital. 
Data was collected about gender, age, smoking status, history of 
NMIBC, pre-operative hydronephrosis, concomitant carcinoma in situ 
(CIS) in TURBT or the cystectomy specimen, lymphovascular invasion 
(LVI), tumor dedifferentiation, positive surgical margins, neoadjuvant 
treatment, postoperative chemotherapy and/or radiotherapy. Surgical 
margins were assessed in bladder, ureters and urethra. Surgical margin 
was scored positive when one or more sites were positive for malignant 
cells. 
Because this was an observational study, based on medical file re-
view, the study does not fall within the scope of the Dutch law on human 
experimentation and is therefore exempt from Institutional Review 
Board approval. 
Follow-up 
Postoperative follow-up schedule included consultation, blood tests 
and imaging of the thorax and abdomen every three months for the first 
year and every six months for the second year. After two years follow-up 
at least once a year was advised. In a substantial number of patients 
follow-up was done in the referring hospitals. In these patients a limited 
set of data regarding recurrence and progression was available. How-
ever, the date of eventual death was collected in all cases. 
If tumor recurrence or (extensive lymph node) metastases were 
diagnosed, patients were most often treated with palliative chemo-
therapy, radiotherapy or immunotherapy. Palliative chemotherapy was 
provided with gemcitabine/cisplatin, gemcitabine/carboplatin or 
MVAC (methotrexate, vinblastine, adriamycin and cisplatin). Occa-
sionally, other combinations of chemotherapy were used. 
Statistical analysis 
Categorical and continuous baseline characteristics of progressive 
and de novo MIBC groups were compared using the Chi-square test and t- 
test, respectively, with p < 0.05 considered as statistically significant. 
Table 1 
Overview of survival rates described in literature for de novo versus progressive MIBC.  
Study Country Study population (No) 5-year overall survival (%) 5-year diseasespecific survival (%) p-value 
Yiou (2002) 21 France De novo 
Progressive 
43 






Schrier (2004) 6 The Netherlands De novo 
Progressive 
89 













58%   
0.074 
Lee (2007) 9 Korea De novo 
Progressive 
173 













51%   
0.473 
Türkölmez (2007) 20 Turkey De novo 
Progressive 
109 






De Vries (2010) 15 The Netherlands De novo 
Progressive 
134 



















Aziz (2013) 14 Germany De novo 
Progressive 
125 






Hidas (2013) 12 Israel De novo 
Progressive 
104 






Masson-Lecomte (2013) 10 France De novo 
Progressive 
155 

































Kayama (2018) 8 Japan De novo 
Progressive 
231 






1. 10-year disease specific survival, 2. Not significant (no p-value noted), 3. Log-rank test, 4. Wilcoxon test, 5. Statistical test could not be identified. 
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Overall survival (OS) was compared using the Kaplan-Meier method. 
The end point was death from any cause and OS was described as years 
between cystectomy and the end point. In case patients were lost to 
follow up, these patients were retrieved from the national Basic Regis-
tration Persons (BRP) on October 22, 2019. For patients who could not 
be retrieved from the BPR (n = 4) or for patients who underwent follow- 
up in our hospital (n = 114) and were still alive before October 2018, the 
date of last appointment was used as the censoring date. Differences 
between the survival rates were compared with the log rank test. To 
assess relevant covariables, a multivariable proportional hazards 
regression model was performed. All analyses were performed using 
SPSS Version 25.0. 
Results 
313 patients (73%) were treated because of de novo MIBC, 118 pa-
tients (27%) because of progressive MIBC. Patient characteristics are 
compared in Table 2. There were only statistically significant differences 
between the groups for clinical T-stage, concomitant CIS and positive 
surgical margins. Concomitant CIS was more frequent in the progressive 
MIBC group than in the de novo MIBC group, 55% and 34%, respectively 
(p < 0.01). Surgical margins also were more frequently positive in pa-
tients with progressive MIBC (24%) than in patients with de novo MIBC 
(13%) (p < 0.01). 
Table 2 










Mean age (years) 65.1 66.3 65.4 0.30 




89 (28)  
92 (78) 










7 (2)  
83 (70) 
34 (29) 











7 (2)  
25 (21) 
86 (73) 





NMIBC diagnosis, n (%) 
Low/intermediate risk 
High risk 
Unknown risk   
23 (19) 
87 (74) 
8 (7)    
















































42 (13)  
60 (51) 
49 (41) 





Pathological lymph node 
























10 (3)  
65 (55) 
51 (43) 













126 (40)  
44 (37) 
29 (25) 












1 (0)  
28 (24) 
90 (76) 












230 (73)  
36 (31) 









266 (85)  
14 (12) 









300 (96)  
3 (3) 









310 (99)  
0 (0) 




Fig. 1. Flowchart of patient selection.  
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Fig. 2 shows a lower overall survival in patients with progressive 
MIBC (p < 0.01). 5-year OS in progressive MIBC patients is 37% and 
49% in de novo MIBC patients. 10-year OS dropped to 20% in the pro-
gressive MIBC group and 39% in the de novo MIBC group. 
To find relevant covariables determining patients’ survival, a uni-
variable and multivariable regression analysis was performed. The re-
sults are shown in Table 3. As expected, in univariable analysis patients 
with pT3–4, N+ and positive surgical margins have a significantly lower 
survival compared to patients with pT2, N0 and negative surgical mar-
gins, respectively. Additional relevant variables in univariable analysis 
are LVI, tumor dedifferentiation and hydronephrosis. Patients with 
progressive MIBC had worse survival compared to patients with de novo 
MIBC with hazard ratio (HR) 1.48 (1.15 – 1.90). All relevant variables in 
univariable analysis were added to a multivariable analysis. Only pT- 
stage, N-stage and LVI remain factors that independently deteriorate 
patients’ survival. Patients with progressive MIBC had worse survival 
compared to patients with de novo MIBC with a borderline significant HR 
1.40 (0.99 – 1.98). 
To determine whether progressive MIBC has a different effect in 
different patient groups, several Kaplan-Meier survival curves were 
made (see Figs. 3 and 4). In Fig. 3 an adverse effect of progressive MIBC 
can be seen in pT2 compared with pT3–4 patients. In Fig. 4 the effect of 
progressive MIBC appears to be detrimental in patients with positive 
surgical margins versus patients with negative surgical margins. Because 
of this difference in effect of progressive MIBC versus de novo MIBC, two 
interaction variables were added to the multivariable analysis. These 
interaction variables did not improve the model, however, with p-values 
of p = 0.69 and p = 0.57, respectively. Apparently, the different effect of 
progressive versus de novo MIBC in the two stage groups and the two 
surgical margin groups disappears when all prognostic factors are taken 
into account. 
Discussion 
Current literature is contradicting regarding the survival of patients 
with NMIBC who progress to MIBC in comparison to patients with de 
novo MIBC. In an earlier collaborative study initiated from our hospital, 
not overlapping with the current study, Schrier et al.6 analyzed 163 
patients and reported a statistically significant better survival in de novo 
MIBC. In the de novo MIBC group 3- and 5-year survival rates were 67% 
and 55% respectively, in contrast with the progressive group with sur-
vival rates of 37% and 28%. The results of Schrier’s study are in line with 
several studies that also reported worse survival in patients with pro-
gressive MIBC7–11. In 2018, Ge et al.5 published a systematic review and 
meta-analysis including 14 studies. Two studies partially contained the 
same study population, so two different meta-analysis hazard ratios 
Fig. 2. 10-year overall survival for de novo and progressive MIBC. Log-rank statistic: p < 0.01.  
Table 3 
Univariable and multivariable Cox regression analysis.   
Univariable analysis Multivariable analysis  
HR (95% CI) p- 
value 
HR (95% CI) p- 
value 
Age 1.02 (1.01 – 
1.03) 







0.89 (0.68 – 
1.17)  
0.40   
Smoking status 
Non/former smoker 
Current smoker  
Ref 
0.99 (0.89 – 
1.10)  
0.86   
Hydronephrosis 2.03 (1.56 – 
2.65) 
< 0.01 1.28 (0.88 – 
1.85) 
0.20 
Progressive MIBC 1.48 (1.15 – 
1.90) 





> pT2  
Ref 















1.79 (1.24 – 
2.58) 
< 0.01 
Concomitant CIS 1.25 (0.99 – 
1.59) 
0.07 1.32 (0.94 – 
1.85) 
0.11 
Lymphovascular invasion 2.98 (2.13 – 
4.17) 
< 0.01 1.69 (1.13 – 
2.53) 
0.01 
Positive surgical margin 2.23 (1.65 – 
3.01) 





1.60 (1.24 – 
2.07) 
< 0.01 0.89 (0.61 – 
1.29) 
0.53  
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were calculated. Model 1, containing the more recent study, showed a 
HR of 1.29 (1.07 – 1.56) and Model 2, containing the larger study, 
showed a HR of 1.19 (0.90 – 1.56). A hypothesized explanation for the 
lower survival in patients with progressive MIBC is stated by Schrier 
et al.6. They presumed that intravesical chemotherapy and immuno-
therapy in patients with NMIBC may cause selection of therapy-resistant 
and more aggressive tumor cell clones, which will progress to MIBC. 
In contradiction with most other studies, Hidas et al.12 and Kotb 
et al.13 reported poorer survival for de novo MIBC. A possible explana-
tion for this difference was stated by Kotb et al., who assumed that pa-
tients with NMIBC were followed according to a more conscientious 
follow-up regimen. If NMIBC would progress into MIBC, these patients 
were diagnosed and treated earlier than patients with de novo MIBC. 
Another possible explanation why progressive MIBC patients in the 
study of Kotb had better survival were the more favorable baseline 
characteristics. The progressive MIBC patients had less hydronephrosis, 
less lymph node invasion, less lymphovascular invasion and less tumors 
were stage T3–4. Several of these variables were not included in 
multivariable analysis. Almost all other available studies reported no 
difference in survival14–21. 
Our study shows that concomitant CIS and positive surgical margins 
are more prevalent in patients with progressive MIBC. This difference in 
positive surgical margins was mainly notable in the ureters (14% in 
progressive MIBC and 3% in de novo MIBC). Surgical margins of the 
Fig. 3. 10-year overall survival in patients with pT2 (A) and pT3–4 (B). Log-rank statistic: (A) p < 0.01; (B) p = 0.30.  
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bladder (9% in progressive and 8% in de novo MIBC) and the urethra (9% 
in progressive and 6% in de novo MIBC) were more similar. Because 
patients with progressive MIBC were more frequently diagnosed with 
CIS, we also find more positive surgical margins with CIS in the ureters 
of these progressive MIBC patients. A positive surgical margin is a 
relevant prognostic factor. The observed difference in effect in KM 
analysis of de novo versus progressive MIBC in patients with and without 
positive surgical margins is caused by other variables. Other studies 
reported no difference in prevalence of positive surgical margins, i.e., 1 – 
8% positive surgical margins in de novo MIBC patients and 3 – 10% in 
progressive MIBC patients7,8,11,13. Also the prevalence of concomitant 
CIS showed no differences with 9 – 49% concomitant CIS in de novo 
MIBC patients versus 16 – 44% in progressive MIBC patients8,11,14,19. 
The higher prevalence of concomitant CIS in progressive MIBC patients 
in our study was not a key factor determining patients’ survival (HR 1.32 
(0.94 – 1.85), p = 0.11). 
In KM analysis progressive MIBC is a strong prognostic factor 
impairing patients’ survival, with a 5- and 10-year OS of 37% and 20%, 
respectively, compared with de novo MIBC with a 5- and 10-year OS of 
49% and 39%. This observed difference maintains when date of MIBC 
diagnosis is used as starting point of follow-up instead of date of radical 
cystectomy, with 5-and 10-year OS of 39% and 20%, respectively, in 
Fig. 4. Effect of progressive MIBC on 10-year OS in patients with negative surgical margins (A) and positive surgical margins (B). Log-rank statistic: (A) p < 0.01; (B) 
p = 0.21. 
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progressive MIBC patients and 5- and 10-year OS of 52% and 40%, 
respectively, in de novo MIBC patients. When included in a multivari-
able analysis, progressive MIBC shows a HR of 1.40 (0.99 – 1.98, p =
0.06). The borderline statistical significance will most likely be caused 
by a lack of power. 
This study has some limitations. Being a third echelon hospital, a lot 
of diagnostic TURBTs were executed in referring hospitals. Also many 
patients returned to the community hospitals for further follow up. This 
causes incompleteness of information about progression or recurrence, 
which made it impossible to determine cancer specific survival. How-
ever, we were able to determine overall survival due to dates of death 
retrieved from the national Basic Registration Persons (BRP). Another 
important limitation of this study is its retrospective character. This may 
also have resulted in incompleteness of data. In a significant number of 
patients (40%), the LVI-status could not be traced down. In future 
(prospective) studies, this is an important variable to determine in every 
patient. It is Furthermore, it is remarkable that the number of cT2 pa-
tients is significantly higher than the number of pT2 patients. Until 2015 
only tumors that were clearly more advanced were classified as cT3 or 
cT4. With the use of neoadjuvant chemotherapy after 2015, it became 
more important to distinguish cT3–4 patients from cT2, which led to less 
misclassification of cT stage. 
Patients with NMIBC have a good prognosis, but when they progress 
to MIBC survival declines considerably. This worse survival is despite 
the strict follow-up regimen of patients with (high risk) NMIBC. A 
radical cystectomy is the preferred treatment option in refractory 
NMIBC, until more robust efficacy data on alternative, more conserva-
tive treatment options will become available22. To improve survival, it is 
important to perform a cystectomy before NMIBC patients progress. This 
study might contribute to the consideration in which patients with 
NMIBC an early cystectomy should be advised. Most patients in this 
cohort with progressive MIBC had a history of high risk NMIBC (n = 87). 
23 patients were previously diagnosed with low or intermediate risk 
NMIBC and 8 were uncertain. The 10 year overall survival of these 3 
groups of progressive MIBC did not differ significantly (log rank p  =
0.46). Because most patients with progressive MIBC had a history of 
high risk NMIBC, considering radical cystectomy is most important in 
the highest risk NMIBC. 
In this study no specific factor could be identified why patients with 
progressive MIBC have worse survival. More studies are needed to 
distinguish a specific subgroup of patients with (high risk) NMIBC who 
remain non-muscle invasive and a subgroup of patients who progress to 
muscle invasive bladder cancer. For a valid prediction of the fate of 
patients with high risk NMIBC, clinical factors alone will probably not 
do the trick. Mutational and transcriptional profiling leading to a mo-
lecular classification of highest risk NMIBC will probably improve such 
prediction.Mutational and transcriptional profiling leading to a molec-
ular classification of highest risk NMIBC will probably improve such 
prediction. 
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